Table 1.
Characteristics of included studies
| Study | Year | Study design | Study population | Number of lesions | Number of cancers | MRI system | Magnetic field strength |
Acceleration method | Contrast agent /injection speed (ml/s) | UF-MRI best model | Reference standard | TN | FN | TP | FP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abe et al | 2016 | Retrospective | D + S | 62 | 33 | Philips | 3 T | PI (SENSE) | Gadobenate dimeglumine /2 | KAUC | Histology + FU | 23 | 5 | 28 | 6 |
| Cao et al | 2023 | Prospective | D | 150 | 117 | Siemens | 3 T | CS (VIBE) | Gadobenate dimeglumine /2 | MS + TTP + TTE + KAUC | Histology | 27 | 11 | 106 | 6 |
| Goto et al | 2018 | Retrospective | D | 107 | 81 | Siemens | 3 T | VS (TWIST) | Gadoterate meglumine/2 | MS + TTE | Histology + FU | 20 | 9 | 72 | 6 |
| Honda et al | 2019 | Retrospective | D | 90 | 61 | Siemens | 3 T | CS (VIBE) | Gadobutrol/2 | TTE | Histology | 15 | 9 | 52 | 14 |
| Kim et al | 2022 | Retrospective | Post operative | 58 | 10 | Philips | 3 T | PI (SENSE) | Gadobutrol/2 | TTE | Histology + FU | 29 | 1 | 9 | 19 |
| Lee et al | 2019 | Retrospective | Preoperative | 202 | 140 | GE | 3 T | VS (DISCO) | Gadoterate meglumine/3 | IEP | Histology + FU | 56 | 35 | 105 | 6 |
| Mann et al | 2014 | Retrospective | D | 199 | 104 | Philips | 3 T | VS (TWIST) | Gadoterate meglumine/2.5 | MS | Histology + FU | 62 | 10 | 93 | 33 |
| Mori et al | 2020 | Retrospective | D (NME) | 77 | 54 | Philips | 3 T | PI (SENSE) | Gadobenate dimeglumine /2.5 | KAUC | Histology + FU | 17 | 10 | 44 | 6 |
| Mus et al | 2017 | Retrospective | D | 195 | 99 | Siemens | 3 T | VS (TWIST) | Gadoterate meglumine/3 | TTE | Histology + FU | 75 | 8 | 91 | 21 |
| Ohashi et al | 2019 | Retrospective | D | 139 | 90 | Siemens | 3 T | VS (KWIC) | Gadobutrol/2.5 | MS | Histology + FU | 31 | 8 | 81 | 19 |
| Onishi et al | 2020 | Retrospective | D + S | 125 | 26 | GE | 3 T | VS (DISCO) | Gadobutrol/2 | MS + BAT | Histology | 87 | 13 | 13 | 12 |
| Pelissier et al | 2021 | Retrospective | D | 210 | 150 | Siemens | 1.5 T | VS (TWIST) | Gadoterate meglumine/2 | MS | Histology + FU | 54 | 24 | 126 | 6 |
| Peter et al | 2020 | Retrospective | D (masses) | 83 | 60 | Siemens | 3 T | VS (TWIST) | Gadoterate meglumine/2 | Peak enhancement | Histology + FU | 14 | 9 | 51 | 9 |
| Ramli et al | 2023 | Prospective | D | 83 | 49 | Siemens | 3 T | VS (TWIST) | Gadoterate meglumine/2 | MS | Histology | 29 | 13 | 36 | 5 |
| Van zeist et al | 2018 | Prospective | S (high risk) | 201 | 31 | Siemens | 3 T | VS (TWIST) | Gadoterate meglumine/2.5 | MS + TTE | Histology | 139 | 5 | 26 | 31 |
| Yamaguchi et al | 2022 | Retrospective | D | 110 | 88 | Siemens | 3 T | CS (VIBE) | Gadobutrol/2.5 | TTE | Histology + FU | 20 | 32 | 56 | 2 |
AI artificial intelligence, BAT bolus arrival time, CNN convoluted neural network, D diagnostic, CS compression sensing, FN false negative, FP false positive, FU follow-up, GE General Electric, IEP initial enhancement phase, KAUC kinetic area under curve, MS maximum slope, MRI magnetic resonance imaging, PI parallel imaging, S screening, TN true negative, TP true positive, TTE time to enhancement, TTP time to peak, VS view sharing